This review provides a comprehensive overview of the development, clinical implementation, and resistance mechanisms of TROP2-targeting ADCs in TNBC and ovarian carcinoma, underscoring their potential to reshape the therapeutic landscape of these challenging cancers. Here, TACSTD2 is linked to cancer.